Cambridge Investment Research Advisors
CNSY

Cambridge Investment Research Advisors’s Cerenome, Inc. Common Stock CNSY Stock Holding History

Cambridge Investment Research Advisors’s Portfolio CNSY Stock Details CNSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-538
Closed -$2K – 4155
2026
Q1 		$2K Hold
538
– – ﹤0.01% 3918
2025
Q4 		$7K Buy
538
+118
+28% +$1.78K ﹤0.01% 3806
2025
Q3 		$7K Buy
+420
New +$5.16K ﹤0.01% 3709
2019
Q3 		– Sell
-1
Closed -$5K – 2393
2019
Q2 		$5K Hold
1
– – ﹤0.01% 2193
2019
Q1 		$5K Buy
+1
New +$5.28K ﹤0.01% 2271

Other funds holding CNSY

ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.79B AUM 27.94% 1-Year Est. Return
APW
Allied Private Wealth Boca Raton, Florida $156M AUM
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.99% 1-Year Est. Return

Cambridge Investment Research Advisors's CNSY Position: Q2 2026 in Review

Cambridge Investment Research Advisors sold out of Cerenome, Inc. Common Stock (CNSY) in Q2 2026, closing a stake of 538 shares — an estimated $2K sold.

Cambridge Investment Research Advisors first reported a position in CNSY in Q1 2019 and held it in 5 quarters. The position peaked at $7K in Q4 2025. 5 funds tracked by Wall St. Rank hold CNSY as of Q2 2026.

  • Cambridge Investment Research Advisors reported no remaining Cerenome, Inc. Common Stock position as of Q2 2026 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 538 Cerenome, Inc. Common Stock shares in Q2 2026, an estimated $2K.
  • Cambridge Investment Research Advisors first reported a position in Cerenome, Inc. Common Stock in Q1 2019 and held it in 5 quarters.
  • Cambridge Investment Research Advisors's Cerenome, Inc. Common Stock position peaked at $7K in Q4 2025.
  • 5 funds tracked by Wall St. Rank held Cerenome, Inc. Common Stock as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.